A Study of the Safety and Effectiveness of GS-5745 in Adults with Moderately to Severely Active Ulcerative Colitis

Overview

About this study

This study will evaluate the effectiveness, safety, and tolerability of GS-5745. It will consist of 2 parts: Induction Study (Cohort 1) and Maintenance Study (Cohort 2). Participants in each part will receive either active GS-5745 or a placebo.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Ulcerative Colitis (UC) confirmed on endoscopy 
  • Moderately to severely active UC (Mayo Score 6-12) 
  • May be receiving
    • Oral 5-aminosalicylate (ASA)
    • Oral corticosteroid
    • Azathioprine
    • 6-mercaptopurine(MP) 
  • Treatment failure with at least one of the following agents received
    • Corticosteroids
    • Immunomodulators
    • Tumor necrosis factor-alpha (TNFα)    antagonists
    • Vedolizumab

 

Exclusion Criteria

  • Diagnosis of Crohn's disease or indeterminate colitis 
  • Pregnant or lactating females 
  • Any chronic medical condition including, but not limited to
    • cardiac disease
    • pulmonary disease
    • alcohol or drug abuse
  • Exhibits severe UC with a clinically significant active infection 
  • History of malignancy in the last 5 years

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Edward Loftus, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20207296

Mayo Clinic Footer